Clinical trials: Castrate-resistant Prostate Cancer
Castration-resistant Prostate Cancer
Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study
Researchers will test a new treatment for prostate cancer. This treatment uses an antibody tagged with a small amount of radioactive material. Researchers believe the new antibody might work better than those used before.
- Trial name
- PROGNOSTICS (NCT06343038)
- Testing
- Injection, 161Tb-SibuDAB,1GBq, Injection, 177Lu-PSMA-I&T, 1GBq, Injection, 161Tb-SibuDAB, Dose Escalation
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Basel, Switzerland
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer
This phase II trial tests how well enzomenib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow or spread…
- Trial name
- NCT07914855
- Testing
- Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Metastatic Prostate Cancer
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who…
- Trial name
- NCT07310433
- Testing
- Dapagliflozin (10mg Tab), standard medical care (ADT + NHA)
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Yung NA
Castrate-Resistant Prostate Cancer
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
- Trial name
- NCT01234025
- Testing
- ISIS EIF4E Rx, Prednisone, Docetaxel
- Where
- 38 sites in United States, Hungary and 4 more
- Volunteers
- 113 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
- Trial name
- NCT06099093
- Testing
- 18F-DCFPyl
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer, Prostate Cancer
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System.
- Conditions
- Breast Cancer, Prostate Cancer, Metastasis
- Trial name
- REaCT-BTA (NCT02721433)
- Testing
- Pamidronate, Denosumab, Zoledronate
- Where
- Canada
- Volunteers
- 263 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer, Endometrial Cancer
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic castration resistant prostate cancer (mCRPC) and…
- Trial name
- NCT03572478
- Testing
- Rucaparib, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Castrate Resistant Prostate Cancer
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
The study has three parts. Part 1 is a dose escalation to investigate the safety and tolerability of ASP9521. Part 2 will evaluate the safety and tolerability and initial anti-tumor activity of ASP9521.
- Trial name
- NCT01352208
- Testing
- ASP9521
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib.
- Trial name
- KHLAD (NCT00953576)
- Testing
- ketoconazole, hydrocortisone, dutasteride
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Metastatic Cancer
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
This will be an open label, Phase I study to assess the efficacy of a reduced 500 mg dose of abiraterone acetate in patients with metastatic prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Cancer, Hormone Sensitive Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT06193993
- Testing
- Abiraterone Acetate
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- National University Hospital, Singapore
Castration-Resistant Prostate Cancer
A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).
- Trial name
- NCT05607693
- Testing
- SHR3680 tablets
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Abiraterone is approved in the United States by the U.S. Food and Drug Administration (FDA) to treat metastatic prostate cancer at 1000 mg daily.
- Trial name
- NCT02415621
- Testing
- Abiraterone Acetate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA…
- Conditions
- Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases
- Trial name
- NCT06706921
- Testing
- 18F-Fluciclovine PET/CT Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostate Cancer, Castration-resistant Prostate Cancer
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response.
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT05081193
- Testing
- Testosterone Undecanoate, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine the safety and efficacy of a novel combination of agents, enzalutamide and everolimus, for the treatment of patients with metastatic castrate-resistant prostate cancer who have never…
- Trial name
- NCT02125084
- Testing
- Everolimus, Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- SCRI Development Innovations, LLC
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle.
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT04729114
- Testing
- PRL-02 injection, prednisone, dexamethasone
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Prostate Cancer
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer
The proposed phase 1 clinical trial will investigate the safety and tolerability of 177Lu-CYT-500 in patients with metastatic prostate cancer and determine the optimal antibody mass and dose of 177Lu to be used for further study.
- Trial name
- CYT-500 (NCT00441571)
- Testing
- 177Lu-CYT-500
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cytogen Corporation
Prostate Cancer, Prostate Cancer Metastatic
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg as a 30 minute IV infusion every 3 weeks.
- Trial name
- NCT04116775
- Testing
- Fecal microbiota transplant, Pembrolizumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Julie Graff, MD
Prostate Cancer
Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer
The main objectives of this trial are: 1. To assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic CRPC who have not received prior chemotherapy. 2.
- Trial name
- NCT01748500
- Testing
- Pantoprazole
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.